Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.13NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.2.13NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-20936.4Hong Kong
BA.2.13NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-21867.4China
BA.2.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.13ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-25657.5Japan
BA.2.13ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.13ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-20165.2Japan
BA.2.13SWuhanCoV-spk1TGTGGTTCATAAAAATTCCTTTGTG25322490024876R-23857.7Japan
BA.2.13SNIID WH-1 F24381R24873ATTTGAAACAAAGACACCTTCAC2334.782485624834R-22193.2Japan
BA.2.13SNIID WH-1 Seq F24383R24865CAAAGACACCTTCACGAGG1952.632484824830R-20677.6Japan
BA.2.69ORF1abYip-ORF1abTTGTTATAGCGGCCTTCTGT204519701951R-21075.5China
BA.2.69ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.69ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.2.69ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-20306.2China
BA.2.69ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
BA.2.69ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-5057.65Germany
BA.2.69ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
BA.2.69ORF1abChan-ORF1abGTGTGATGTTGAWATGACATGGTC2441.671635316330R-13317.5China
BA.2.69ORF1abHKU-ORF1bAACRCGCTTAACAAAGCACTC2142.861890918889R-17655.9Hong Kong
BA.2.69SYoung-SATCCAGCCTCTTATTATGTTAGAC2437.52187621853R-22070.7Singapore
BA.2.69SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-22073.5China
BA.2.69SWon-SCACCTGTGCCTGTTAAACCA20502321323194R-21965.9South Korea
BA.2.69EWon-ECACACAATCGATGCGCAGTA20502636526346R-19261.4South Korea
BA.2.69ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.69EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
BA.2.69ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BA.2.69NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.69NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-3370.08Thailand
BA.2.69NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.69NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.69NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BA.2.69NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.69NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-22527.5Germany
BA.2.69NWon-NGTTGCGACTACGTGATGAGG20552884928830R-23088.1South Korea
BA.2.69NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.2.69NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-20936.4Hong Kong
BA.2.69NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-21867.4China
BA.2.69NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.69ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-25657.5Japan
BA.2.69ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.69ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-20165.2Japan
BA.2.69SWuhanCoV-spk1TGTGGTTCATAAAAATTCCTTTGTG25322490024876R-23857.7Japan
BA.2.69SNIID WH-1 F24381R24873ATTTGAAACAAAGACACCTTCAC2334.782485624834R-22193.2Japan
BA.2.69SNIID WH-1 Seq F24383R24865CAAAGACACCTTCACGAGG1952.632484824830R-20677.6Japan
BA.2.60ORF1abYip-ORF1abTTGTTATAGCGGCCTTCTGT204519701951R-21075.5China
BA.2.60ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.60ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.2.60ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-20306.2China
BA.2.60ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
BA.2.60ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-9191.15Germany
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used